Device Exemption News Today

NEW YORK & AACHEN, Germany, April 02, 2024--Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the enrollment of the first patient in the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816). The trial will enroll between 250-500 randomized patients undergoing transcatheter aortic valve replacement (TAVR) in the USA and Europe with the ProtEmbo® System, an innovative next generation cerebral embolic protec...

Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the completion of a ? 30 million Series B financing round to support the enrollment of the PROTEMBO Investigational Device Exemption (IDE)...

$46.4 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025Topline efficacy data for VenoValve® U.S. pivotal trial to be presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024Continued progress towar...

EnVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial ...

/PRNewswire/ -- Endovascular Engineering ("E2"), a medical device company focused on the development and deployment of groundbreaking clot removal technologies...

3Spine, Inc., a medical device company developing a transformational alternative to lumbar spinal fusion, today announced achievement of US clinical trial enrol

3Spine, Inc., a medical device company developing a transformational alternative to lumbar spinal fusion, today announced achievement of US clinical trial enrol

03.01.2024 - Appointment brings more than 30 years of medical technology general management and commercial leadership experience to the InspireMD team Reports inducement grant under NASDAQ listing rule 5635(c)(4) TEL AVIV, Israel and MIAMI, Jan. 03, 2024 ... Seite 1

OnPoint Vision has developed a 4.5 millimeter lens to help treat macular degeneration

Cordis has acquired MedAlliance, a Swiss-based medical technology company, in a transaction valued at USD 1.135 billion.